• Explore /
  • Poster
  • / Results from a phase 3, randomized, double-blind, multicenter, placebo-controlled trial of orteronel (TAK-700) plus prednisone in patients with metastatic castration-resistant prostate cancer (mCRPC) that has progressed during or following docetaxel-based therapy (ELM-PC 5 trial).

Results from a phase 3, randomized, double-blind, multicenter, placebo-controlled trial of orteronel (TAK-700) plus prednisone in patients with metastatic castration-resistant prostate cancer (mCRPC) that has progressed during or following docetaxel-based therapy (ELM-PC 5 trial).

Abstract Poster

Authors

Robert Dreicer

Robert Dreicer

Cleveland Clinic, Cleveland, OH

Robert Dreicer , Robert Jones , Stephane Oudard , Eleni Efstathiou , Fred Saad , Ronald De Wit , Johann Sebastian De Bono , Yuanjun Shi , Bindu Tejura , David B. Agus , Niels Geert Borgstein , Joaquim Bellmunt , Karim Fizazi

Sign-In to See More Abstracts, Journal Articles, Posters, Videos and Slides and to Bookmark Your Favorite Content.

Disclaimer

This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org

Poster Details

Meeting

2014 Genitourinary Cancers Symposium

Session Type

Poster Session

Session Title

General Poster Session A: Prostate Cancer

Track

Prostate Cancer

Sub Track

Prostate Cancer

Clinical Trial Registration Number

NCT01193257

Citation

J Clin Oncol 32, 2014 (suppl 4; abstr 7^)

DOI

10.1200/jco.2014.32.4_suppl.7

Abstract #

7^

Poster Bd #

C7

Abstract Disclosures

Similar Posters

First Author: Daniel Petrylak

First Author: F. Saad

First Author: Oscar B. Goodman Jr.

First Author: Christopher Sweeney